CGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cognition Therapeutics Inc (CGTX) is not a strong buy for a beginner investor with a long-term focus at this time. The technical indicators are bearish, the financial performance is weak with significant losses, and there are no strong trading signals or significant positive catalysts to justify immediate investment. It is better to wait for further clarity on the company's financial improvement or progress in its drug pipeline.
The technical indicators for CGTX are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 46.716, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level (0.861) with resistance levels at 1.109 and 1.262, and support levels at 0.612 and 0.459.
The company has received nearly $200 million in grants from the National Institutes of Health, and its lead drug candidate CT1812 has shown promising results in Phase 2 trials for dementia and Alzheimer's disease. Additionally, the CEO is actively presenting updates at healthcare conferences, which could increase visibility.
Revenue remains at 0, showing no growth. There are no significant insider or hedge fund trading trends, and the stock's technical indicators are bearish.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$3,343,000 (-57.37% YoY), and a significant decline in EPS (-77.78% YoY). Gross margin remains at 0, indicating no profitability.
No recent analyst ratings or price target changes are available for CGTX.
